Influence of body weight on the performance of glomerular filtration rate estimators in subjects with type 2 diabetes.
نویسندگان
چکیده
The American Diabetes Association recommends estimation of glomerular filtration rate (GFR) (1) by either the Cockcroft-Gault (2) or the Modification of Diet in Renal Disease (MDRD) (3) equation in all patients with diabetes. The implication is that these equations provide similar results. Body weight is a numerator in the CockcroftGault equation; however, it is absent from the MDRD equation. This may explain some of the difference in the ability of these equations to estimate GFR in patients with type 2 diabetes, over 80% of whom are obese (4), and may lead to discrepancies in reporting of chronic kidney disease stage (5). Our study was designed to identify whether body weight may explain variability in performance between the Cockcroft-Gault and MDRD equations in patients newly diagnosed with type 2 diabetes.
منابع مشابه
The Association of Glomerular Filtration Rate with Coronary Artery Disease in Type 2 Diabetic Patients
Objective: Chronic kidney disease (CKD) and diabetes mellitus can influence coronary artery disease (CAD) independently. The aim of this study was to evaluate the association of glomerular filtration rate (GFR) and CAD in type 2 diabetic patients (T2DM). Materials and Methods: This cross sectional study evaluated 3624 T2DM patients with clinical presentation of CAD whose documents were registe...
متن کاملAn Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors
We systematically reviewed the anti-atherosclerotic effects beyond glucose lowering of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with diabetes, and found that SGLT-2 inhibitors are proved to be significantly associated with weight loss and reduction of blood pressure, in addition to lowering plasma glucose, by a relatively large number of studies [1]. However, the studies in...
متن کاملEffects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis
BACKGROUND Sitagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the inactivation of incretins, increasing the endogenous active incretin levels. Incretins stimulate insulin secretion from pancreatic β-cells and inhibit glucagon secretion from pancreatic α-cells, which is favorable for the treatment of diabetes. Sitagliptin is released on December, 2009, in Japan. We...
متن کاملAerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study
BACKGROUND Patients with obesity, diabetes, and chronic kidney disease (CKD) are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. METHODS We performed a 24-week randomized controlled feasibility study comparing aerobic exercise plus optimal medical management to medical management alone in patients with type 2 diabetes, obesity (body mass in...
متن کاملDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
AIMS Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have diuretic-like physiologic effects, we compared dapagliflozin and hydrochlorothiazide (HCTZ) effects on 24-h ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Diabetes care
دوره 31 1 شماره
صفحات -
تاریخ انتشار 2008